Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-01

Clinical Trial Update: A Study of TL-925 for the Treatment of Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for TL-925 in allergic conjunctivitis (status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TL-925

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: UNKNOWN